Vericel Stock News

Equities analysts predict that Vericel Co. (NASDAQ:VCEL) will post earnings per share of $0.20 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Vericels earnings, with the lowest EPS estimate coming in at $0.17 and the highest estimate coming in at $0.22. Vericel reported earnings per share of []

This is a reversal of the price action on the previous day, in which price moved down. The post Vericel Corp (VCEL): Price Now Near $39.11; Daily Chart Shows Downtrend on 100 Day Basis appeared first on ETF Daily News .

Knee Cartilage Damage Repair Market research report is wide-ranging and object-oriented which is framed after the combination of an admirable industry experience, talent solutions, industry insight, and most modern tools and technology. A thorough analysis has been performed in this

Invesco Ltd. trimmed its position in shares of Vericel Co. (NASDAQ:VCEL) by 37.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 432,649 shares of the biotechnology companys stock after selling 256,976 shares during the period. Invesco Ltd. owned 0.93% of Vericel worth $22,714,000 []

Zacks Investment Research upgraded shares of Vericel (NASDAQ:VCEL) from a sell rating to a hold rating in a research report released on Saturday morning, Zacks.com reports. According to Zacks, Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two []

Vericel Co. (NASDAQ:VCEL) was the target of unusually large options trading on Friday. Investors purchased 4,195 put options on the stock. This is an increase of 2,297% compared to the typical daily volume of 175 put options. In other news, Director Steven C. Gilman sold 5,000 shares of the firms stock in a transaction dated []

Royal Bank of Canada grew its position in Vericel Co. (NASDAQ:VCEL) by 169.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 96,615 shares of the biotechnology companys stock after acquiring an additional 60,722 shares during the period. Royal Bank of Canadas holdings in Vericel []

MetLife Investment Management LLC trimmed its position in Vericel Co. (NASDAQ:VCEL) by 10.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,730 shares of the biotechnology companys stock after selling 1,902 shares during the quarter. MetLife Investment Management LLCs holdings in Vericel were []

Hanseatic Management Services Inc. raised its position in Vericel Co. (NASDAQ:VCEL) by 9.4% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 13,721 shares of the biotechnology companys stock after acquiring an additional 1,175 shares during the period. Vericel makes up 1.2% of Hanseatic Management Services Inc.s investment []

Vericel Co. (NASDAQ:VCEL) Truist Securiti decreased their FY2021 earnings per share estimates for Vericel in a report released on Tuesday, November 9th. Truist Securiti analyst S. Brodovsky now expects that the biotechnology company will post earnings of ($0.09) per share for the year, down from their previous estimate of $0.08. Truist Securiti also issued []

CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Co

Vericel Corporation (VCEL) CEO Nick Colangelo on Q3 2021 Results - Earnings Call Transcript

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -266.67% and -11.12%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the st

Vericel (NASDAQ:VCEL) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the followin